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1. Introduction  
Microparticles ( MP) are small membrane bound vesicles which have been described in 
circulation. They are derived from a variety of cells by an active process of shedding. They 
are bound by plasma membrane, are anucleate but may contain DNA or RNA and may be 
virtually derived from any cell (Ahn 2005, Mause, et al, Porto, et al). The majority of the 
microparticles in blood are derived from platelets. Previously considered as cell debris they 
are now regarded as vectors for transfer of biological information. The MP production is 
thought to reflect a balance between cell stimulation, proliferation and death. Based on their 
potential function and pathophysiologic effect, MP are thought to be physiological or 
patholological. MP play a role in normal haemostasis and abnormal amplification of MP 
production leading to a pathological state (Meziani, et al). For example, excessive MP from 
platelets may contribute to thrombosis (Siljander, et al 1996). Their role in vascular biology is 
being uncovered with increasing evidence for their role in venous thromboembolism. This 
chapter will explore the role of these MP in the physiology of haemostasis as well as 
pathology of thromboembolism. The final section will discuss the current state of art in the 
methods used to detect and measure MP. 
1.1 Definition of a microparticle  
Microparticles are submicron (<1.0µm) membrane bound circulating vesicles. Although 
anucleate, usually express cell surface antigen specific to the cell of origin, they may contain 
DNA or RNA and be virtually derived from any cell  (Freyssinet 2003). The ISTH  
(International Society of Thrombosis and Haemostasis) vascular biology subcommittee 
defined these particles as being between 0.1-1.0 µm (SSCMembers Aug 2005). However, 
several other nanoscale techniques have demonstrated that particles <0.1 µm may also need 
to be considered as MP  (Yuana, et al). Indeed, size range of MP is contentious with larger 
MP likely overlapping with small platelets and the smallest MP with exosomes (Gyorgy, et 
al, Jy, et al, Lawrie, et al 2009). Several factors may cause the production of MP from cells 
such as activation, complement mediated lysis, shearing stress, oxidative injury and active 
vesiculation (Horstman, et al 2004). The MP bear at least some surface characteristics of the 
parent cell and they differ from exosomes (0.03-0.1µm), which originate through the 
exocytosis of endocytic multivesicular bodies and play a role in antigen presentation 
(Freyssinet and Dignat-George 2005, Horstman, et al 2004, Horstman, et al 2007). 
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Cellular source of MPs Marker Proportion in circulation 
Platelets 
 
 
CD61 (GPIIIa)
CD63 
CD62p (P-selectin) 
CD41 
80-90%
Leucocytes CD45 <5%
Erythrocytes Glycophorin A 5-10%
T helper cells CD4 <1%
T cytotoxic cells CD8 <1%
B cells CD20 <1%
Monocytes/ macrophages CD14 <5%
Endothelial cells CD62e (E-selectin) <5%
Table 1. Microparticle source, surface antigen expression and proportion in circulation  
(Enjeti, et al 2007, Siljander). 
2. Microparticles: Production and role in haemostasis  
2.1 How are microparticles produced? 
Microparticles are thought to be produced by an active process of vesiculation or shedding 
from the cell surface and utilizing ATP in the process. Various enzymes involved in the 
production of MP have been studied. The balance of several enzymes regulating membrane 
homeostasis is believed to be key in the production of MP. An inward aminophospholipid 
enzyme ‘translocase’ or ‘flippase’and an outward enzyme ‘floppase’ have been postulated to 
maintain the dynamic symmetrical state of the phophoslipid bilayer membrane (Diaz and 
Schroit 1996, Montoro-Garcia, et al, Morel, et al). In a resting membrane the flippase enzyme 
is more active thereby ensuring that phosphotidyl serine (PS) is at the inner membrane.The 
activation of phospholipid nonspecific enzyme known as ‘scramblase’ is said to be 
responsible for disruption of membrane asymmetry and several mechanisms participating 
in the regulation of the transmembrane migration of phosphatidylserine (PS) in activated 
cells lead to microparticle shedding (Diaz and Schroit 1996, Enjeti, et al 2008, Morel, et al 
2006). After stimulation, calcium is released from intracellular stores. Calcium depletion 
induces the activation of store-operated calcium entry (SOCE) through channels in the 
plasma membrane and this process is thought to be regulated by transient receptor potential 
channel (TRPC) proteins  (Diaz and Schroit 1996, Montoro-Garcia, et al). The transverse 
redistribution of PS is under the control of SOCE. Several other process such as Raft 
integrity, cytoskeleton organization and MAP kinase pathway (Ras-ERK) are also involved 
in membrane remodelling (Diaz and Schroit 1996, Montoro-Garcia, et al, Morel, et al 2006). 
Microparticles typically have phosphotidyl serine on the outer surface (although PS 
negative MP have also been recently described) and ABCA1, a member of the ATP-binding 
cassette family of transporters, is a potential candidate for the transport of PS to the surface 
(Diaz and Schroit 1996, Morel, et al 2006). 
2.2 Role of MP in coagulation and haemostasis 
Normal coagulation is a complex process triggered by endothelial damage and exposure of 
tissue factor and collagen which initiates a platelet plug formation at the site of injury. This 
www.intechopen.com
 
Microparticles: Role in Haemostasis and Venous Thromboembolism 5 
leads to activation of a cascade of enzymes, which forms a fibrin clot. Microparticles of 
different cell origin could play a role in fibrin clot formation, enhance platelet leukocyte 
interactions and influence other plasma proteins such as von Willebrand’s factor. Given that 
platelet MP constitute the majority of the circulating MP, they are considered an important 
effector of the haemostatic process (Morel, et al 2006). Some MP have also been described to 
carry molecules with anticoagulant function on their surface (Freyssinet 2003). The balance 
of pro and anticoagulant bearing MP in the endovascular milieu is likely to influence the 
propensity to bleed or clot in a particular patient. 
 
Type of MP Example of surface marker on MP 
Procoagulant von Willebrand's Factor 
Tissue Factor 
Platelet Factor 3 activity 
Anti-coagulant Tissue Factor Pathway inhibitor 
Protein C/S 
Thrombomodulin 
Table 2. The possible pro and anticoagulant markers on the surface of microparticles  (Enjeti, 
et al 2007, Morel, et al 2006). 
2.3 Platelet MP  
2.3.1 Platelet MP and coagulation 
Traditionally, platelets major function was thought to be due to their aggregability and 
ability to plug damaged endothelium and capillary vessels. More recently, they are thought 
to form an important substrate for the coagulation pathway with their membrane providing 
the surface for the formation of the prothrombinase complex (comprising the Xa and Va 
complex). This enzyme complex leads to conversion of fibrinogen to fibrin which in 
combination with a variety of other factors leads to a stable clot at the site of injury. The 
presence of platelet microparticles at the site of blood vessel injury may contribute to this 
process by providing a large source of surface membrane for assembly of the enzymatic 
process. Indeed the exposure of phosphotidylserine at the site of thrombin generation 
increases the enzymatic catalyic effect by several hundred fold (Aleman). Platelets thus 
appear to have two major physiological roles for achieving haemostasis - form a platelet 
plug at the site of endothelial injury and generate microparticles which provide a surface for 
activation of the coagulation cascade leading to formation of the fibrin clot. The third 
possible role for the platelet MP could possibly be in maintaining the integrity of normal 
resting endothelium (Cambien, 2004). This area is still being actively explored. The role of 
MP in haemostasis is illustrated in figure 1. 
Apart from procoagulant function MP could also be involved in anticoagulant activity. 
Microparticles with TFPI (tissue factor pathway inhibitor) and antithrombin activity have 
been described (Morel, et al 2006, Siljander). However, the anticoagulant MP have not been 
as extensively studied and it would be interesting to evaluate these MP - its association with 
pathologic conditions.  
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Fig. 1. The interaction of MP of platelet and monocyte origin being recruited in thrombus 
formation at site of endothelial injury. 
2.3.2 Molecular interactions of Platelet MP  
Platelet MP also bear a number of antigens such GPIIbIIIa, GPIa, von Willebrand’s factor 
and arachidonic acid which may all be important effectors in the clotting mechanism. The 
understanding of the molecular mechanisms of haemostasis has now led to the thinking that 
coagulation can be described as an interaction between p-selection, tissue factor thrombin 
and microparticles  (Furie and Furie 2004). P-selectin is an adhesion molecule expressed at 
the platelet endothelial interface which is thought to be critical for tissue factor activity and 
leukocyte adhesion in the thrombus (Myers, 2003). Some authors have even described P-
selectin on microparticles, tissue factor and clotting proteins as being the molecular triad for 
coagulation (Polgar, 2005). 
Another potential role of MP may be in the interaction of endothelium, von Willebrand’s 
factor and platelets.The platelet derived microparticles could interact with the protease 
ADAMTS-13 (A Disintegrin And Metalloproteinase with ThromboSpondin-1-like motifs, 
member 13 of this family of metalloprotease) , which regulates the activity of high molecular 
weight von Willebrand’s factor. Increased microparticles in circulation could potentially 
compete in binding ADAMTS-13, reducing its interaction with the endothelium and 
influencing multimer cleavage  (Jy, et al 2005). This may then contribute to the increased 
rates of thrombosis observed in these patients with thrombotic thrombocytopaenic purpura 
though the evidence for this process is very preliminary. 
Endothelial disruption
Tissue factor exposed at
Microparticle recruitment
Monocyte interaction
Endothelial cell
circulating
platelet
fibrin polymerization
Platelet aggregation
Collagen in adventitia
site of endothelial injury and haemostasis
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2.4 Tissue factor bearing MP  
In an intact blood vessel tissue factor is usually restricted to adventitia and protected by the 
endothelial layer. However, small amounts of monocyte related tissue factor have been 
isolated in circulation  (Key). The presence of tissue factor (TF) bearing microparticles, 
mainly derived from monocytes, in circulation has been shown to participate in initiation of 
fibrin polymerization (Eilertsen and Osterud 2004, Key). Although usually found to be in 
very small numbers in normal circulation, these increase dramatically at the site of injury. 
The interaction between tissue factor bearing MP and platelet MP is also of interest as there 
appears to be some evidence that they may be complementary in terms of thrombin 
generation potential (Key and Kwaan). 
2.5 Modelling MP in thrombosis 
The evidence for the involvement of these MP in its various physiological roles in 
haemostasis comes from the following models. 
2.5.1 Cell based haemostasis model 
The initial evidence for the role of MP in haemostasis comes from the cell based model. In 
this model plasma coagulation proteins are activated on the membrane surface after 
exposure to tissue factor. This leads to enzymatic cleavage of thrombin from prothrombin 
which ultimately converts fibrinogen to fibrin. This forms the fibrin clot and leads to 
haemostasis along with other components of the clot such as platelets and monocytes (Biro, 
et al 2003, Chirinos, et al 2005). 
2.5.2 Live imaging model  
Studies using intravital microscopy have shown that TF bearing MP derived from 
haemopoietic cells are incorporated into a thrombus. A laser injury model using the 
cremaster muscle arterioles of the mouse showed that MP participate in thrombosis (Falati, 
et al 2003). Although these studies visualize incorporation of TF bearing MP into the 
thrombus, it is not yet known if these MP are actually functional. 
2.5.3 Animal models  
These studies have involved introducing exogenous MP from patients or other source into 
animal models. In one such study MP from patients with acute coronary syndrome were 
introduced in to a rat model triggered venous thrombosis (Mallat, et al 2000). This study 
supports the role of TF bearing MP in promotion of VTE, However, the cellular sources of 
this TF has not been entirely clarified in other studies (Shantsila, et al). 
2.5.4 Scott Syndrome  
Scott Syndrome is an extremely rare hemorrhagic disorder characterized by bleeding 
diathesis ( only three well documented cases of Scott syndrome have been reported to date)  
(Zwaal, et al 2004). The bleeding tendency is thought to be due to impaired procoagulant 
activity of stimulated platelets – the platelets being unable to expose anionic phospholipids 
and to shed procoagulant microparticles. The exposure of the aminophospholipids, mainly 
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phosphatidylserine, on surface of stimulated platelets or derived microparticles, is critical 
for the formation of enzyme complexes in the clotting process (Zwaal, et al 2004, Zwaal, et al 
2005). Mutations involving the ABCA1 ATP transporter have been reported in this 
syndrome (Zwaal, et al 2004).  
There are several other mechanisms by which MP influence the endovascular system. They 
may modulate endothelial function and carry proangiogeneic molecules (Lozito and Tuan). 
Recently MP bearing Sonic hedgehog have been shown modulate angiogenesis  (Soleti, et al 
2009, Soleti and Martinez 2009). They may also serve as novel carriers for transport of 
genetic material – such as mRNA or microRNA and these are currently areas of intense 
research (Rak). 
3. Role in thrombosis 
From their role in physiology of haemostasis it can be extrapolated that excess production of 
MP will lead to a pathological state. Indeed, increase in circulating MP have been described 
in a wide variety of states. The role of MP in various thrombotic states is discussed below. 
3.1 Venous Thromboembolism (VTE) 
3.1.1 Idiopathic VTE  
Venous thromboembolism is the result of a complex interaction between the circulating 
proteins, cells/platelets and the endothelium (Collen and Hoylaerts 2005). There is no 
known provoking or identifiable precipitating factor in idiopathic VTE. A recent study 
looked at the interactions between the MP of various origin - platelet, endothelial and 
monocyte and endothelial derived MPs were found to be elevated in association with VTE. 
One report suggests that the combination of total circulating MP, P-selectin levels and D-
dimer levels may help predict VTE (Rectenwald, et al 2005). This approach had a sensitivity 
of 73% indicating the need for further refinement for application in clinical practise. 
In another larger investigation no association was found between levels of total circulating 
MP and risk of recurrent VTE (Ay, et al 2009). Interestingly, a study comparing patients with 
cancer who had VTE and those with idiopathic VTE found raised tissue factor bearing MP 
only in cancer patients (Thaler, et al). In another report, plasma levels of tissue factor MP 
were not raised in those with pulmonary embolism suggesting that that perhaps other 
subtypes of MP may have to be studied in more detail to explain the relationship found in 
experimental models (Garcia Rodriguez, et al 2010). Owen  and co authors looked at the 
recurrence of VTE and found that the procoagulant activity but not number of MP was 
increased in cases of recurrence (Owen, et al).  
The role of MP in predicting thrombosis in those with heritable thrombophilia has also been 
explored. It has been found that total circulating MP levels were increased in subjects with 
heterozygote factor V Leiden status but there was no difference between those who had had 
VTE and those without (Enjeti, et al 2010). This finding and other studies seems to suggest 
that although total microparticles have been shown to be increased in those with VTE or 
those prone for VTE, there appears to be no convincing data that MP help to predict or 
monitor VTE. However, in a recent study that investigated this issue further, looked at MP 
levels by a different approach by comparing percentiles of MP measured in a retrospective 
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case-control fashion. In those with circulating MP above the 90th percentile of the control 
population’s distribution, a five fold increased risk was observed (Bucciarelli, 2011). They 
found that elevated MP were indeed an independent risk factor for VTE and this warrants a 
confirmation in a prospective cohort study. 
The draw back of the studies in this area of VTE include the variability of type of MP 
studied, the techniques employed for measurement of MP and retrospective nature of 
investigations undertaken. 
3.1.2 Immune related VTE  
In contrast to idiopathic VTE, there is strong evidence for involvement of MP in 
thrombogeneticity in patients with underlying immune disorders. Important examples 
include antiphospholipid antibody syndrome and heparin induced thrombocytopaenia with 
thrombosis syndromes (Combes, et al 1999, Dignat-George, et al 2004, Walenga, et al 2000). 
Markedly elevated platelet derived MP have been desccribed in both clinical syndromes 
(Hughes, 2000). There is experimental evidence to suggest that circulating autoantibodies 
trigger the formation of excess MP contributing to the prothrombotic process in these 
patients. Circulating MP in these syndromes have been shown to expose GPIb,GPIIbIIIa, P-
selectin and thrombospondin all of which help promote thrombosis (Jy, et al 2007). 
3.1.3 Microparticles, VTE and cancer  
In contrast to the above discussion for idiopathic VTE  – thrombosis, cancer and 
microparticles seem to have a more definitive relationship. The MP are thought to reflect a 
balance between cell stimulation, proliferation and death which may be important in cancer 
related thrombosis. Cancer increases the risk of VTE by four fold and addition of 
chemotherapy further increases the risk by six to eight fold (Furie and Furie 2006). It is 
possible that circulating MP shed from cancer cells represent an indication for tumours to 
metastasize in the absence of any other clinical evidence for metastasis. A recent report 
states that platelet MP markedly stimulated the metastatic potential of 5 different cancer cell 
lines (Rak). It has also been shown that human tumor derived MP when injected into mice 
activated coagulation by virtue of their TF procoagulant activity (Thaler). 
Procoagulant properties of tumor cell MP have been an area of intense study. A range of  
endothelial, monocyte and leukocyte MP along with tissue factor bearing MP appear to have 
a coagulant potential and have shown to be elevated in various such as cancers such as 
pancreatic, breast and prostate  (Pilzer, et al 2005, Simak and Gelderman 2006). 
A recent in vivo live microscopy mouse model with pancreatic cancer demonstrated that TF 
bearing MP released from the cancer cells entered circulation and participated in the 
thrombus formation at a distant site (Thomas, 2009). 
The most important evidence for role of MP in VTE and cancer comes from clinical studies 
showing increased numbers and procoagulant activity of MP in cancer (Langer). Elevated 
levels of tissue factor bearing MP were associated with VTE events in those with advanced 
malignancy particularly pancreatic cancer. The microparticle levels in cancer patients also 
predicted the development of thrombosis, with the one year estimate of those with TF 
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bearing MP being about 34% (Thaler, 2011). In contrast those who did not develop 
thrombosis did not have a detectable level of tissue factor bearing microparticles. 
3.1.4 Disease groups associated with venous or arterial thrombosis 
There are a number of conditions associated with elevated MP. Most of these disease states 
are associated with an increased risk of thrombosis. They essentially seem to reflect the 
health and pathophysiology of the endovascular system. Table 3 below gives a list of 
conditions where they have been found to be elevated. 
 
Condition Specific example where MP were elevated 
(reference) 
Cardiovascular disease Hypertension (Boulanger) 
Myocardial infarct/angina (Nagy) (Exner, 
2005 ) 
Stroke (Merten, 2004) 
Diabetes (Alkhatatbeh) 
Thromboembolism (Cimmino) 
Myeloproliferative Disorder Polycythemia vera (Duchemin) 
Essential Thrombocytosis (Villmow, 2002) 
Myelofibrosis (Villmow, 2002) 
Thrombotic Microangiopathies Thrombotic thrombocytopaenic purpura 
(Ahn, 2002) 
Pre-eclampsia of pregnancy (Aharon) 
Autoimmune diseases Antiphopholipid antibody syndrome 
(Combes, 1999;Dignat-George, 2004) 
Systemic lupus erythematosis (Nielsen; 
Pereira, 2006) 
Cancer related  Metastatic solid tumours (Dass, 2007) 
Chemotherapy induced (Kim, 2002; Kim) 
Neoangiogenesis (Goon, 2006 ) 
Table 3. List of conditions associated with thrombosis and elevated MPs in circulation. 
3.2 Microparticles and atherothrombosis  
The role of MP in promoting atherothrombosis has also been another area of study 
(Cimmino). In one report, shed membrane microparticles were seen to be produced in 
human atherosclerotic plaques and were a critical determinant of thrombogenecity after 
plaque rupture (Mallat, 1999). The apoptosis occurring after plaque disruption or rupture 
was closely associated with TF expression on cell membranes leading to thrombogenecity. 
These MP were observed to express phosphotidylserine and some expressed CD11a which 
is an adhesion molecule (Martinez, 2005) (Morel, 2006). Given the links between 
inflammation and thrombosis, the emerging role of MP in atherothrombosis is not 
surprising (McGregor, 2006; Meerarani, 2007). 
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4. Measuring microparticles  
There are several approaches to detection and measurement of MP. The methods are usually 
based on the ability of the assay to either enumerate or assess functional activity of the MP.  
4.1 Functional assays  
Most of the assays under this section relate to either the prothrombotic function of MP or 
measuring the phospholipid content of MP. This can be done in the liquid phase e.g. a clot 
based assay such as the XACT test or by estimation of prothrombinase activity using an 
ELISA (Exner, 2003). The advantages of these approaches are that they provide an indication 
of the procoagulant activity of MP. The drawback is that the cell of origin for the MP cannot 
be determined. 
4.2 Quantitative assays  
Flow cytometry is the most widely employed quantitative technique. The gating of small 
particles continues to be a challenge but flow cytomtery continues to be the only robust 
technique which can demonstrate the cell of origin for the MP. This is an important asset of 
flow cytometry. However, there is significant variability amongst flow cytometers and the 
ISTH subcommittee on vascular biology recently conducted a workshop on standardization 
of MP by flow cytometry (Lacroix). It remains a popular approach for detection of MP for 
the following reasons:1)Rapid turn around time 2)Both fresh and frozen specimens may be 
used 3)The expression of two or more antigens on the MP may be simultaneously 
demonstrated 4)Easy method for quantification using commercial beads. 
However it has the following drawbacks: 1) The detection of particles less than 0.3µm is 
difficult by flow cytometry as the detection is limited by particle size in the same order of 
magnitude wavelength of the laser ( about 488 nm 2) Different machines have different 
sensitivities 3) It is difficult to automate 4) Centrifugation speeds for sample processing are 
variable and not standardized (Freyssinet, 2005). Several new approaches to flow cytometry 
include using impedance flow cytometry and using Raman microspectrophotometry effect 
to cover the size and particle discrimination issues (Ayers, 2011). 
The capture of MP into immobilized annexin V or cell specific antibodies using an ELISA 
based assay have ben the other major approaches (Enjeti, 2007). Solid phase assays have the 
advantage of picking up microparticles irrespective of size. However interference of soluble 
antigens, variable quality of antibodies used for antigen capture  and non-exclusion of 
microsomes are some of the disadvantages. 
4.3 Nanoscale and newer technologies  
In the recent years there has been an adaptation of nanoscale technologies such as atomic 
force microscopy and nanoparticle measurement techniques. These methods claim to 
accurately measure particles in the nanoscale size range (Yuana). For example , one such 
nanoscale technique uses the brownian motion of these small particles to detect and 
measure them (Harrison, 2009).  These methods are expensive, intensive to perform and not 
yet widely available (Lawrie, 2009). Moreover, the clinical utility of such techniques is not 
yet established. Recently a proteomic approach to analysis of MP has been described, 
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however, the clinical utility of this approach is also as yet unkown (Howes ; Ramacciotti). 
Automated devices to analyse MP are also being developed (Wagner, 2010). 
4.4 Measuring microparticles: Future directions 
There are several outstanding issues such as standardization of preanalytical and analytical 
variables as well as integration of the various approaches in measuring MP. Several novel 
approaches are now being considered. 'Megamix beads' is novel approach to standardizing 
of gating of microparticles using flow cytometry. It uses a mix of a 0.9um and 0.3um sized 
beads to try and capture all events within the gate set by the beads (Robert, 2009 ;Robert, 
2011). One of the problems of using this approach is the lack of linearity in the relationship 
between the size of beads and forward sctatter at that particle size. A recent commercially 
available nanoscale technology known as ‘Nanosight‘ has incorporated antibody tagging of 
small particles for accurate identification and counting in this size range (Harrison, 2009). 
5. Conclusions  
Utility of Measuring MP in venous thromboembolism is yet to be fully established . The case 
for measuring MP in cancer related VTE is perhaps stronger. There are three areas within 
which the potential for detecting and measuring MP with respect to venous 
thromboembolism may be relevant. 
5.1 Diagnostic   
The evidence for using measurement of MP in a diagnostic setting is limited. The studies so 
far have shown variable results depending on whether TF bearing MP, functional activity or 
total MP were measured. With respect to VTE MP have been assessed in the paradigm of 
VTE, diagnosis in a small pilot study where it was shown that D-dimer, P-selectin and total 
MP levels predicted thrombosis as demonstrated on Doppler ultrasound (Ramacciotti; 
Rectenwald, 2005). The role of MP in diagnosis of VTE warrants confirmation in prospective 
cohort studies. The standardization of measurement of MP will go a long way in ensuring 
comparability of such studies. 
5.2 Prognostic  
The potential for MP as a prognostic tool is dependent on reliable, reproducible and easily 
available tools to measure microparticles. There is emerging data that MP may predict VTE 
in cancer patients and may be able to provide prognostic information in several other 
conditions. 
5.3 Therapeutic 
An interesting dimension to this area is the approach to use or modify MP for therapeutic 
benefit. The possibility of bioengineered and/or harvested membrane microparticles in 
tissue repair or angiogenesis is being investigated (Soleti, 2009). The MP are also being 
studied as a drug delivery tool (Benameur, 2009). Microparticles could potentially be 
specifically targeted to reduce or prevent thrombotic complications or end organ damage 
(Myers, 2005). This is an promising and exciting new area for researchers and clinicians 
working in this area. 
www.intechopen.com
 
Microparticles: Role in Haemostasis and Venous Thromboembolism 13 
Microparticles have therefore emerged as key role players in vascular biology and 
pathophysiology of thrombosis. They remain an important research tool and their clinical 
applications are being actively investigated with potential to be applied in diagnostic, 
prognostic and therapeutic arenas. They are small yet powerful effectors for the 
pathophysiology of the endovascular system. 
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